AGER and prostate cancer: The cell response to S100A4 is receptor-mediated, cell-specific, and dependent on the conformation of S100A4 or on the association with several other receptors such as the receptor of advanced glycation end products (RAGE) on various cell types including human chondrocytes and prostate cancer cells [26, 27].